Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$335.48 -0.3%	$342.83	$267.83 ▼ $391.29	$181.00B	0.44	2.70 million shs	681,153 shs
BOLT Bolt Biotherapeutics	$5.26 -0.8%	$4.73	$3.91 ▼ $7.35	$10.11M	1.1	26,277 shs	17,921 shs
CRIS Curis	$0.55 +4.7%	$0.58	$0.46 ▼ $3.13	$21.24M	3.08	531,873 shs	102,400 shs
DOMH Dominari	$3.65 +5.7%	$3.09	$2.68 ▼ $8.40	$84.00M	0.69	149,225 shs	258,515 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	+0.12%	-0.28%	-0.91%	-13.31%	+20.86%
BOLT Bolt Biotherapeutics	+2.06%	+17.41%	+11.34%	+19.23%	-10.60%
CRIS Curis	-0.87%	+6.82%	-10.08%	-54.09%	-74.96%
DOMH Dominari	+11.65%	+6.81%	+21.05%	+13.86%	-26.91%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$335.48 -0.3%	$342.83	$267.83 ▼ $391.29	$181.00B	0.44	2.70 million shs	681,153 shs
BOLT Bolt Biotherapeutics	$5.26 -0.8%	$4.73	$3.91 ▼ $7.35	$10.11M	1.1	26,277 shs	17,921 shs
CRIS Curis	$0.55 +4.7%	$0.58	$0.46 ▼ $3.13	$21.24M	3.08	531,873 shs	102,400 shs
DOMH Dominari	$3.65 +5.7%	$3.09	$2.68 ▼ $8.40	$84.00M	0.69	149,225 shs	258,515 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	+0.12%	-0.28%	-0.91%	-13.31%	+20.86%
BOLT Bolt Biotherapeutics	+2.06%	+17.41%	+11.34%	+19.23%	-10.60%
CRIS Curis	-0.87%	+6.82%	-10.08%	-54.09%	-74.96%
DOMH Dominari	+11.65%	+6.81%	+21.05%	+13.86%	-26.91%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMGN Amgen	2.48	Hold	$355.19	5.88% Upside
BOLT Bolt Biotherapeutics	2.40	Hold	$34.67	559.06% Upside
CRIS Curis	1.67	Reduce	$17.00	3,002.19% Upside
DOMH Dominari	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest CRIS, DOMH, BOLT, and AMGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2026	BOLT Bolt Biotherapeutics	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$22.00
5/28/2026	BOLT Bolt Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$7.00
5/22/2026	CRIS Curis	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
5/20/2026	AMGN Amgen	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$400.00 ➝ $375.00
5/14/2026	AMGN Amgen	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$432.00 ➝ $427.00
5/13/2026	AMGN Amgen	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$410.00 ➝ $390.00
5/7/2026	AMGN Amgen	Freedom Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/5/2026	AMGN Amgen	Erste Group Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/4/2026	AMGN Amgen	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$351.00 ➝ $340.00
5/1/2026	AMGN Amgen	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$332.00
5/1/2026	AMGN Amgen	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$325.00 ➝ $327.00

(Data available from 5/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMGN Amgen	$37.22B	4.86	$33.75 per share	9.94	$17.03 per share	19.70
BOLT Bolt Biotherapeutics	$6.50M	1.56	N/A	N/A	$10.32 per share	0.51
CRIS Curis	$9.44M	2.26	N/A	N/A	$0.33 per share	1.66
DOMH Dominari	$123.10M	0.67	N/A	N/A	$1.40 per share	2.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMGN Amgen	$7.71B	$14.37	23.34	14.24	3.37	20.96%	137.41%	13.28%	8/4/2026 (Estimated)
BOLT Bolt Biotherapeutics	-$33.38M	-$16.33	N/A	N/A	N/A	-455.15%	-100.89%	-48.23%	8/13/2026 (Estimated)
CRIS Curis	-$7.58M	-$1.19	N/A	N/A	N/A	-80.29%	N/A	-181.57%	8/4/2026 (Estimated)
DOMH Dominari	-$22.43M	-$4.03	N/A	N/A	N/A	-31.37%	-206.20%	-155.26%	N/A

Latest CRIS, DOMH, BOLT, and AMGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2026	Q1 2026	DOMH Dominari	-$0.17	-$2.11	-$1.94	-$3.17	$35.81 million	$35.81 million
5/12/2026	Q1 2026	BOLT Bolt Biotherapeutics	-$2.85	-$4.31	-$1.46	-$4.31	$1.50 million	$0.03 million
5/12/2026	Q1 2026	CRIS Curis	-$0.3267	-$1.25	-$0.9233	-$1.25	$1.69 million	N/A
4/30/2026	Q1 2026	AMGN Amgen	$4.77	$5.15	+$0.38	$3.34	$8.58 billion	$8.62 billion
3/19/2026	Q4 2025	CRIS Curis	-$0.4325	-$0.50	-$0.0675	$1.23	$3.25 million	$1.14 million
3/12/2026	Q4 2025	BOLT Bolt Biotherapeutics	-$4.27	-$3.84	+$0.43	-$3.84	$0.67 million	$2.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMGN Amgen	$10.08	3.00%	+8.27%	70.15%	14 Years
BOLT Bolt Biotherapeutics	$0.36	6.84%	N/A	N/A	N/A
CRIS Curis	N/A	N/A	N/A	N/A	N/A
DOMH Dominari	N/A	N/A	N/A	N/A	N/A

Latest CRIS, DOMH, BOLT, and AMGN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/4/2026	AMGN Amgen	quarterly	$2.52	3.09%	5/15/2026	5/15/2026	6/5/2026
5/4/2026	DOMH Dominari	special	$0.31		5/15/2026	5/15/2026	5/29/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMGN Amgen	5.65	1.26	1.01
BOLT Bolt Biotherapeutics	0.98	3.51	3.51
CRIS Curis	N/A	1.11	1.11
DOMH Dominari	N/A	1.41	1.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMGN Amgen	76.50%
BOLT Bolt Biotherapeutics	86.70%
CRIS Curis	29.97%
DOMH Dominari	42.48%

Insider Ownership

Company	Insider Ownership
AMGN Amgen	0.85%
BOLT Bolt Biotherapeutics	9.40%
CRIS Curis	5.42%
DOMH Dominari	55.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMGN Amgen	31,500	539.71 million	535.12 million	Optionable
BOLT Bolt Biotherapeutics	90	1.92 million	1.74 million	Not Optionable
CRIS Curis	60	38.98 million	36.87 million	No Data
DOMH Dominari	4	22.61 million	10.11 million	Not Optionable

CRIS, DOMH, BOLT, and AMGN Headlines

Recent News About These Companies

Dominari Holdings Restructures Series B Warrants for Capital

May 27 at 6:51 PM | tipranks.com

Dominari Holdings Congratulates Cerebras Systems on "Blockbuster" Initial Public Offering

May 15, 2026 | prnewswire.com

Dominari Holdings Issues Shareholder Letter

May 13, 2026 | prnewswire.com

Dominari Q1 Revenue Increases by 395% Over Q1 2025

May 13, 2026 | prnewswire.com

Dominari (DOMH) Projected to Post Quarterly Earnings on Wednesday

May 6, 2026 | marketbeat.com

Dominari Holdings Inc. (NASDAQ:DOMH) Announces $0.31 Special Dividend

May 4, 2026 | marketbeat.com

Dominari Holdings Announces Record Date for Cash Dividend

May 4, 2026 | prnewswire.com

Dominari 2025 Revenue Surges 487% in 2025, Balance Sheet Strengthens Significantly

March 31, 2026 | prnewswire.com

Dominari Releases Letter to Shareholders and Clients

March 16, 2026 | prnewswire.com

New American Drone and Defense Company to be Created Through Merger of Powerus and Aureus Greenway Holdings

March 9, 2026 | globenewswire.com

Dominari Holdings Expands 2022 Equity Incentive Plan Authorization

March 5, 2026 | tipranks.com

Dominari Holdings Announces Change of Record Date and Payment Date for $10 Million Cash Dividend

December 12, 2025 | prnewswire.com

Dominari (NASDAQ:DOMH) COO Sells $173,250.00 in Stock

December 11, 2025 | insidertrades.com

Dominari Holdings Announces $10 Million Cash Dividend

December 11, 2025 | prnewswire.com

Dominari Expands Strategic Leadership with Appointment of Ambassador Jamie McCourt to Advisory Board

December 8, 2025 | prnewswire.com

Dominari (NASDAQ:DOMH) COO Christopher Franklin Devall Sells 40,000 Shares of Stock

December 6, 2025 | insidertrades.com

Dominari 2025 Revenue Surges 703% in First Nine Months, Balance Sheet Strengthens Significantly

November 11, 2025 | prnewswire.com

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Dominari Holdings Inc. (NASDAQ: DOMH)

October 27, 2025 | prnewswire.com

Dominari Securities Raises Over $1.4 Billion Year-to-Date in Support of American Innovation and Entrepreneurship

October 16, 2025 | prnewswire.com

Trump brothers-backed Dominari Holdings cleared to lead IPOs on NYSE

October 9, 2025 | msn.com

Dominari Board Member Steps Down to Become Interim CFO

September 24, 2025 | marketwatch.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CRIS, DOMH, BOLT, and AMGN Company Descriptions

Amgen NASDAQ:AMGN

$335.48 -1.00 (-0.30%)

As of 02:14 PM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Bolt Biotherapeutics NASDAQ:BOLT

$5.26 -0.04 (-0.75%)

As of 02:11 PM Eastern

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Curis NASDAQ:CRIS

$0.55 +0.02 (+4.70%)

As of 02:14 PM Eastern

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Dominari NASDAQ:DOMH

$3.64 +0.20 (+5.65%)

As of 02:13 PM Eastern

Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRIS, DOMH, BOLT, and AMGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRIS, DOMH, BOLT, and AMGN Earnings

Compare Dividends

Latest CRIS, DOMH, BOLT, and AMGN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRIS, DOMH, BOLT, and AMGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CRIS, DOMH, BOLT, and AMGN Company Descriptions

Amgen NASDAQ:AMGN

Bolt Biotherapeutics NASDAQ:BOLT

Curis NASDAQ:CRIS

Dominari NASDAQ:DOMH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools